Keyword search
Filter results by
Search HelpKeyword(s)
Subject
Survey or statistical program
Results
All (4)
All (4) ((4 results))
- Articles and reports: 88-003-X20010035971Geography: CanadaDescription:
Biotechnology firms are generally flexible and innovative in their approaches to survival and growth in Canada and also on the world stage. Read an overview of some of the business strategies and practices used by biotechnology firms to conduct research and development and for some, commercialization of their products.
Release date: 2001-10-31 - Articles and reports: 88-003-X20010035972Geography: CanadaDescription:
Based on information from the 1997 Biotechnology Firm Survey, we know biotechnology firms generated $813 million in biotech revenues; employed 9,000 people in biotech-related activities and had almost 9,000 products across all stages of development. Explore issues such as - What are the main features of this sector? What is the extent of networking activities by the firms? And what kinds of problems are they facing when selling their products?
Release date: 2001-10-31 - 3. Canadian Biotechnology Industrial Activities: Features from the 1997 Biotechnology Survey ArchivedArticles and reports: 88F0006X2001012Description:
As of 1997, Canadian biotech industry was made of 282 core firms. Of these, 214 were small firms with less than 50 employees, 37 were medium firms with 51 to 150 employees, and 31 were large firms with over 150 employees. They earned $813 million from biotech products sales, $311 million of which were from exports. They employed 9,000 people in biotech related activities and had 8,924 products at all stages of development. Private placements, venture capital and labour sponsored funds were these firms main sources of financing capital. Access to capital was the most serious obstacle faced by the biotech firms in 1997. Marketing and distribution were their major reasons for entertaining strategic alliances, while universities were their most preferred R&D partners.
Release date: 2001-09-25 - 4. Federal Government Expenditures and Personnel in the Natural and Social Sciences, 1991-1992 to 2000-2001 ArchivedArticles and reports: 88F0006X2001008Description:
This document presents historical tables displaying Federal Government expenditures and personnel in the Natural and Social Sciences, 1991-92 to 2000-2001. Expenditures and personnel for each fiscal year to 1998-99 are actual while the data for 1999-2000 and 2000-2001 are forecasts and estimates respectively.
Release date: 2001-05-23
Data (0)
Data (0) (0 results)
No content available at this time.
Analysis (4)
Analysis (4) ((4 results))
- Articles and reports: 88-003-X20010035971Geography: CanadaDescription:
Biotechnology firms are generally flexible and innovative in their approaches to survival and growth in Canada and also on the world stage. Read an overview of some of the business strategies and practices used by biotechnology firms to conduct research and development and for some, commercialization of their products.
Release date: 2001-10-31 - Articles and reports: 88-003-X20010035972Geography: CanadaDescription:
Based on information from the 1997 Biotechnology Firm Survey, we know biotechnology firms generated $813 million in biotech revenues; employed 9,000 people in biotech-related activities and had almost 9,000 products across all stages of development. Explore issues such as - What are the main features of this sector? What is the extent of networking activities by the firms? And what kinds of problems are they facing when selling their products?
Release date: 2001-10-31 - 3. Canadian Biotechnology Industrial Activities: Features from the 1997 Biotechnology Survey ArchivedArticles and reports: 88F0006X2001012Description:
As of 1997, Canadian biotech industry was made of 282 core firms. Of these, 214 were small firms with less than 50 employees, 37 were medium firms with 51 to 150 employees, and 31 were large firms with over 150 employees. They earned $813 million from biotech products sales, $311 million of which were from exports. They employed 9,000 people in biotech related activities and had 8,924 products at all stages of development. Private placements, venture capital and labour sponsored funds were these firms main sources of financing capital. Access to capital was the most serious obstacle faced by the biotech firms in 1997. Marketing and distribution were their major reasons for entertaining strategic alliances, while universities were their most preferred R&D partners.
Release date: 2001-09-25 - 4. Federal Government Expenditures and Personnel in the Natural and Social Sciences, 1991-1992 to 2000-2001 ArchivedArticles and reports: 88F0006X2001008Description:
This document presents historical tables displaying Federal Government expenditures and personnel in the Natural and Social Sciences, 1991-92 to 2000-2001. Expenditures and personnel for each fiscal year to 1998-99 are actual while the data for 1999-2000 and 2000-2001 are forecasts and estimates respectively.
Release date: 2001-05-23
Reference (0)
Reference (0) (0 results)
No content available at this time.
- Date modified: